ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#05

June 2026

Medetomidine Is Replacing Xylazine in the Fentanyl Supply. Naloxone Will Not Reverse It.

Xylazine has been a known adulterant in the fentanyl supply since 2022. Medetomidine is its more potent successor, now appearing alongside or in place of xylazine in illicit fentanyl samples across multiple U.S. markets. A 2026 clinical review (PMC11930164) provides the most complete current picture: medetomidine is a veterinary alpha-2 adrenergic agonist that is more pharmacologically potent than xylazine at the alpha-2 receptor, produces a longer duration of sedation, and causes the same vasoconstrictive wound complications. Like xylazine, its sedation is not reversed by naloxone.

The clinical toxidrome matters: fentanyl combined with medetomidine produces both opioid and alpha-2 sedation. Naloxone addresses the opioid component. Medetomidine sedation requires supportive care, including airway management and sustained monitoring. Patients presenting with skin wounds and a history of illicit opioid use may have medetomidine exposure whether or not a standard urine drug screen reflects it. Medetomidine is not on standard immunoassay panels; detection requires LC-MS/MS with medetomidine specifically included in the confirmation menu. Most clinical laboratory menus as of mid-2026 do not include it.

NIH/PMC. Responding to Medetomidine: Clinical and Public Health Needs. PMC. 2026. PMCID: PMC11930164  ·  Full text →

Effective: June 10, 2026

DOT Oral Fluid Rule Is Now Operative. Zero Labs Are Certified. Here Is What That Means.

The Department of Transportation's final rule under 49 CFR Part 40 took effect June 10, 2026. The rule mandates oral fluid testing for DOT-covered safety-sensitive transportation programs, with a specific contingency: when no HHS-certified oral fluid laboratory exists, the employer must substitute a directly observed urine collection. As of the June 1, 2026 HHS Federal Register certified laboratory list, zero HHS-certified oral fluid laboratories exist for federal testing purposes. The direct observation fallback is operative now, not at some future date.

The path to oral fluid testing under this rule works as follows: once HHS certifies a second oral fluid laboratory and issues a formal announcement, an 18-month transition window begins before oral fluid testing becomes mandatory. Until that announcement, directly observed urine collection is the required substitute. Workplace drug testing programs, medical review officers, and any consultants advising on DOT compliance programs need to update their protocols to reflect this. There is currently significant market confusion about whether DOT oral fluid is operationally "live." The answer: the rule is legally operative, but the laboratory infrastructure is not in place, and directly observed urine is the required bridge.

For drug court and OTP consulting context: state-level oral fluid adoption is moving on a separate track from federal DOT compliance. Georgia, Arizona, Colorado, Indiana, New York, and Utah each have oral fluid statutes for law enforcement or public assistance programs that are not subject to the 49 CFR Part 40 framework and are not waiting on HHS laboratory certification. If you advise programs on oral fluid options, the applicable framework depends on whether the testing program is DOT-covered.

DOT Final Rule. 49 CFR Part 40. 91 Fed. Reg. (May 11, 2026). Effective June 10, 2026.  ·  HHS Certified Laboratory List: Federal Register, June 1, 2026 →

SYSTEMATIC REVIEW / RCT META-ANALYSIS

Buprenorphine-Naloxone vs. Methadone: Neither Is Universally Superior. Here Is What the RCT Data Show.

A systematic review and meta-analysis of randomized controlled trials comparing buprenorphine-naloxone and methadone for opioid use disorder found that neither medication is uniformly superior. Methadone demonstrated higher 6-month treatment retention. Buprenorphine-naloxone showed a more favorable safety profile with fewer serious adverse events, greater reductions in opioid use in patients with comorbid mental health disorders, and improvements in cocaine craving and cardiac parameters. The authors conclude that treatment selection should be individualized based on the patient's specific clinical profile rather than a blanket formulary preference.

Systematic review and meta-analysis of RCTs. PubMed. 2026.  ·  PMID 40536198 →